In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
This method could help ... Immune Sensitivity Links Race and Survival After Prostate Cancer Immunotherapy Oct. 17, 2024 — Black men with advanced prostate cancer have a greater chance of ...
Dendreon's prostate cancer immunotherapy Provenge has been rejected by NICE in draft guidance, which said its high price and weak evidence based meant it could not be recommended. Provenge ...
The Mike Slive Foundation has named the recipients of six prostate cancer research grants. The grants are aimed at continuing the foundation’s stated mission of ending prostate cancer. 39 prostate ...
The latest prostate cancer immunotherapy research shows that PCa evades immune detection by downregulating major histocompatibility complex class I (MHCI) through androgen receptor (AR).